Testicular, Penile, and Rare Malignancies

InPACT Trial Seeks to Determine Best Treatment Sequencing for Penile Cancer

Guidance addresses prepubic fat coverage and dose fractionation for both neoadjuvant and adjuvant settings.

Latest News

Evaluating Cemiplimab in la/mPC: New Findings From the Phase II EPIC-A Trial

Emily MenendezTesticular, Penile, and Rare Malignancies | February 13, 2025

The EPIC-A trial has demonstrated the efficacy and safety of cemiplimab combined with platinum-based chemotherapy for la/mPC.

Retroperitoneal Lymph Node Metastasis in Testicular Cancer: MRI, CT Show Comparable Accuracy

Emily MenendezTesticular, Penile, and Rare Malignancies | February 7, 2025

Specificity findings varied, but some studies suggested similar or slightly higher rates in favor of MRI.

First-Line PD-1 Blockade, Cisplatin, Paclitaxel Effective for Advanced PSCC in Retrospective Study

Emily MenendezTesticular, Penile, and Rare Malignancies | January 18, 2025

There is a lack of data on 1L regimens for distant metastatic PSCC, with a 2-year OS rate of just 21%.

Challenges in Treating Penile Cancer

Andrea Necchi, MDTesticular, Penile, and Rare Malignancies | September 16, 2024

Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.

TIP Combination Provides 5-Year OS, PFS Benefits for Second-Line GCTs

Emily MenendezTesticular, Penile, and Rare Malignancies | August 1, 2024

Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.

Cabozantinib, Nivolumab With or Without Ipilimumab Improves ORR for GU Cancers

Emily MenendezUrothelial Carcinoma | July 9, 2024

A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer

RLT

Renal Cell Carcinoma

Localized Renal Cell Carcinoma

Urothelial Carcinoma

Advanced Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Prostate Cancer

RLT

Renal Cell Carcinoma

Localized Renal Cell Carcinoma

Conference Coverage

Dr. David Canes on WellPrept - Boosting Patient Education and Improving Care

David Canes, MDUrothelial Carcinoma | May 7, 2025

Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.

Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology

Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025

Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.

ctDNA in GU Oncology: History, Current Studies, and Benefits

John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025

John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.

cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?

Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025

Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.

Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection

Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025

Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.

Exploring Survival Outcomes of nccRCC With Tumor Thrombus Extension

Joseph Cheaib, MDnccRCC | May 5, 2025

Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.